Trading update for the ten months ended 31 October 2026
Growth accelerating in the second half
London, UK, 18 November 2026 – Convatec, a leading medical products and technologies company focused on solutions for the management of chronic conditions, announces its trading update for the ten months ended 31 October 2026.
Key points
- YTD organic revenue growth1 ex-InnovaMatrix of 6.6%2. YTD organic growth including InnovaMatrix of 3.7%; reported growth 4.8%3
- Stronger H2 growth in Infusion Care and Continence Care
- Upgrading FY26 Group revenue growth expectations to 6.25-7.0% (previously 5.5-6.5%)
Accelerating organic revenue growth; increased FY26 guidance for CC and IC
- Advanced Wound Care (AWC) was low-to-mid single digit ex-InnovaMatrix YTD, similar to H1. ConvaFoam continued to gain share and Aquacel AG+ Extra grew slightly ahead of soft markets
- We continue to expect mid-single digit growth ex-InnovaMatrix in FY26
- InnovaMatrix: we now expect FY26 revenue of c.$5m (previously $5-10m)
- Ostomy Care (OC) was mid-single digit YTD, similar to H1. Our 1-piece soft convex product, Esteem Body, continued to gain share
- Our 2-piece soft convex product, Natura Body, is on track to launch in mid-2027
- We continue to expect mid-single digit OC growth in FY26
- Continence Care (CC) accelerated to mid-to-high single digit growth YTD, from increased US new patient volumes and further strong growth outside the US, each supported by excellent customer service. Our compact catheter, GentleCath Air for Women, continued to gain share
- Cure Aqua began launching in September; GentleCath Air Pocket and GentleCath Air Set in November
- We now expect mid-to-high single digit CC growth in FY26 (previously MSD)
- Infusion Care (IC) accelerated to double-digit growth YTD, driven by faster H2 diabetes growth and continued strong growth in AbbVie’s treatment of Parkinson’s disease
- Improved execution delivered increased manufacturing volumes
- We now expect double-digit IC growth in FY26 (previously HSD)
FY26 Group guidance and medium-term financial targets
- Group organic revenue growth1 ex-InnovaMatrix 6.25-7.0%
- Adjusted operating profit margin of at least 23% (unchanged). This includes c.65 bps adverse FY26 FX headwinds and c.90 bps InnovaMatrix headwind
- Double-digit growth in adjusted EPS (unchanged)
- Reiterating our medium-term targets: 6-8% organic revenue and double-digit adjusted EPS growth; reaching mid-20s% adjusted operating margin from 2027
Jonny Mason, Chief Executive Officer, commented:
“Revenue growth has accelerated in the second half, as we expected. We saw notable strength in Infusion Care, where improved execution enabled us to meet rising demand, ahead of new capacity coming online in 2027. Overall, we continued to gain share in all categories, underpinned by new product launches."
“We are making good progress executing our Accelerate strategy, the next exciting chapter of Convatec’s story. We are investing to accelerate growth, supporting our new product launches which are winning share with healthcare professionals and users. We are improving execution and are positioned to deliver sustainable 6-8% revenue growth and double-digit annual EPS growth, supporting more people around the world with innovative, trusted medical solutions for chronic conditions.”
Other FY26 guidance
- Total capex at the upper end of $200-230m range. Within this, growth capex at the upper end of $135-165m range as we accelerate expanding capacity
- $200m share buyback on track to complete in FY26
- Adjusted net finance expense of c.$75m (previously $70-75m)
- Adjusted book tax rate of c.23% (unchanged); cash tax increasing c.400bps YoY to c.16%
- Cash costs of adjusting items of c.$30m (previously $20m)
- c.90% equity cash conversion (previously c.100%), with strong working capital inflow in H2 partly offset by increases in cash tax and adjusting items
Foreign exchange and macroeconomic environment
- If current spot rates hold for the remainder of FY26, the estimated tailwind to FY26 revenue growth will be c.90 bps (previously 130 bps) and the headwind to operating margin will be c.65 bps (previously 40 bps)
Launches, innovation and pipeline
- AWC: our early phase ConvaNiox European launch continues to receive excellent user feedback. Reimbursement is now available in the UK community setting via NHS drug tariff. Recruitment in our US diabetic foot ulcer randomised controlled trial is now complete (300 patients), with results expected in 2027, while the US De Novo submission is ongoing. Indication expansion has been submitted in Europe, and our commercial footprint has extended to Australia. ConvaVAC and ConvaFiber are on limited European release, with US full launch expected in 2027
- OC: Esteem Body growth remains ahead of expectations, with segment share now up to c.15%; our two-piece equivalent Natura Body is on track to launch in mid-2027. This will remove a gap for soft convex products in our portfolio, essential for growth in the US
- CC: GentleCath Air for Women continued to win share in compact catheters in the US and Europe. Cure Aqua, our new ready-to-use hydrophilic catheter, started launching in September and GentleCath Air Pocket and GentleCath Air Set, our compact male and unisex catheter, in November, completing a gap for compact, ready-to-use hydrophilic catheters in our portfolio
- IC: our Inset Guard platform technology in diabetes is broadening the form factors we serve, with more and varied pump types including our first hybrid patch pump (announced in May 2026). We are also supporting additional new advanced Parkinson's disease therapies
Conference call details
Jonny Mason, Chief Executive Officer, and Fiona Ryder, Chief Financial Officer, will host a conference call for analysts and investors to discuss the trading update at 8:30am (UK time) on 18 November 2026. To access the live webcast, please register here.
To ask questions and join by conference call, please register here to receive dial-in details.
Contacts
Investor Relations: IR@convatec.com
Media: mediarelations@convatec.com
About Convatec
Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With over 10,000 colleagues, we provide products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention, treatment for hard to heal wounds, at-risk skin and ulcerated tissue to supporting debilitating conditions, improved patient outcomes and reduced care costs. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit http://www.convatecgroup.com.
All product and programme names are trademarks of Convatec and its subsidiaries, including: InnovaMatrix®, ConvaFoam™, ConvaNiox™, Aquacel®, Aquacel™ ConvaFiber™, ConvaVAC™, Esteem Body™, Esenta™, Natura® Body, Flexi-Seal™ Air, Cure™ Aqua, GentleCath Air™ for Women, GentleCath Air™ for Men, GentleCath Air Pocket™, GentleCath Air Set™, Neria™ Guard, Inset™ Guard and Convatec me+ programme.
Forward Looking Statements
This document includes certain forward-looking statements with respect to the operations, performance and financial condition of the Group. Forward-looking statements are generally identified by the use of terms such as “believes”, “estimates”, “aims”, “anticipates”, “expects”, “intends”, “plans”, “predicts”, “may”, “will”, “could”, “targets”, “continues”, or their negatives or other similar expressions. These forward-looking statements include all matters that are not historical facts.
Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant business, economic and competitive uncertainties and contingencies that are difficult to predict and many of which are outside the Group’s control. As such, no assurance can be given that such future results, including guidance provided by the Group, will be achieved. Forward-looking statements are not guarantees of future performance and such uncertainties and contingencies, including the factors set out in the “Principal Risks” section of the Strategic Report in our Annual Report and Accounts, could cause the actual results of operations, financial condition and liquidity, and the development of the industry in which the Group operates, to differ materially from the position expressed or implied in the forward-looking statements set out in this document. Past performance of the Group cannot be relied on as a guide to future performance.
Forward-looking statements are based only on knowledge and information available to the Group at the date of preparation of this document and speak only as at the date of this document. The Group and its directors, officers, employees, agents, affiliates and advisers expressly disclaim any obligations to update any forward-looking statements (except to the extent required by applicable law or regulation). LEI number - 213800LS272L4FIDOH92
[1] Organic revenue growth is calculated by applying the applicable prior period average exchange rates to the Group's actual performance in the respective period and excluding acquisitions and divestitures.
[2] In the ten months to 31 Oct 2026, non-InnovaMatrix revenue represented over 99.5% of Group revenues.
[3] US dollar depreciation YoY drove c.1.1% FX revenue translation benefit YTD.
Press Release